Medivation, Inc. Elects Wendy L. Yarno to Board of Directors

SAN FRANCISCO, CA--(Marketwired - April 29, 2013) - Medivation, Inc. (NASDAQ: MDVN) today announced that Wendy Yarno has been elected to the Company's Board of Directors. Ms. Yarno has over 26 years of experience in the pharmaceutical industry at Merck & Co. Inc., holding a number of executive positions in the marketing, sales and human resources areas. Ms. Yarno most recently served as Chief Marketing Officer at Merck, a position from which she retired in 2008.

"Wendy is an accomplished executive and her unique mix of experience in both the commercialization of pharmaceutical products and human resources management makes her an excellent addition to our board of directors," said David Hung, M.D., president and chief executive officer of Medivation, Inc. "We are pleased to welcome her to the team and value the expertise she brings to Medivation."

"Medivation is well positioned for future growth and I look forward to working with the team to scale the organization and take full advantage of the commercial opportunities that lie ahead and to help Medivation continue its success and evolution with other potential product candidates," said Ms. Yarno.

In 2008, Ms. Yarno retired from Merck following a 26-year career at the company in commercial and human resource positions of increasing seniority, most recently Chief Marketing Officer. In that role, Ms. Yarno led a global organization charged with all aspects of supporting pre- and post-launch commercialization of pharmaceuticals in more than 20 therapeutic areas. She also previously served as General Manager, Cardiovascular/Metabolic U.S. Business Unit, where she had P&L responsibility for Merck's largest therapeutic area, and as Senior Vice President, Human Resources.

Ms. Yarno currently serves on the Board of St. Jude Medical and also serves on the Advisory Board and Board of Directors of multiple privately held health care companies.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at www.medivation.com.